Care Bare Rx vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Care Bare Rx
Best for LGBTQ+-inclusive compounded GLP-1 telehealthStarting at $199/mo
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launchStarting at $149/mo
Side-by-Side Comparison
| Feature | Care Bare Rx | Ro |
|---|---|---|
| Overall Score | 7.4/10 | ✓7.9/10 |
| Starting Price | $199/mo | ✓$149/mo |
| Editorial Rating | 3.7 ★ /5 | ✓4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Care Bare Rx
Pros
- ✓Explicit LGBTQ+-inclusive, 'self-care with pride' positioning — one of the few GLP-1 telehealth brands with this framing
- ✓All 50 states + Puerto Rico coverage
- ✓Offers both compounded options ($199/mo) and brand-name Ozempic ($705/mo) — unusual flexibility in the compounded-first telehealth segment
- ✓Same named medical team as Breeze Meds and Synergy Rx: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
- ✓Four named 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx)
- ✓No FDA warnings or litigation on record
Cons
- ✗Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Breeze Meds and Synergy Rx — the three brands are white-labeled storefronts on top of one underlying operation, not three independent providers
- ✗Compounded medications are not FDA-approved
- ✗Despite the LGBTQ+ positioning, no formal gender-affirming care pathway or HRT integration is mentioned — the inclusive framing is editorial rather than a clinical specialty
- ✗Limited accreditation transparency beyond LegitScript claim — no PCAB/ACHC seal on site
- ✗Pharmacy partners are named but per-batch third-party testing and accreditation details are not independently disclosed
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Ro edges out Care Bare Rx with a higher overall score of 7.9/10 and is particularly strong for broadest GLP-1 formulary including Foundayo on day-one of launch. Care Bare Rx remains a solid alternative, especially if you're looking for LGBTQ+-inclusive compounded GLP-1 telehealth.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.